SG10201607346XA - Angiopoietin-like 4 and its use in modulating cell leakiness - Google Patents

Angiopoietin-like 4 and its use in modulating cell leakiness

Info

Publication number
SG10201607346XA
SG10201607346XA SG10201607346XA SG10201607346XA SG10201607346XA SG 10201607346X A SG10201607346X A SG 10201607346XA SG 10201607346X A SG10201607346X A SG 10201607346XA SG 10201607346X A SG10201607346X A SG 10201607346XA SG 10201607346X A SG10201607346X A SG 10201607346XA
Authority
SG
Singapore
Prior art keywords
angiopoietin
modulating cell
leakiness
cell leakiness
modulating
Prior art date
Application number
SG10201607346XA
Inventor
Nguan Soon Tan
Original Assignee
Univ Nanyang Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nanyang Tech filed Critical Univ Nanyang Tech
Publication of SG10201607346XA publication Critical patent/SG10201607346XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
SG10201607346XA 2011-08-08 2012-08-08 Angiopoietin-like 4 and its use in modulating cell leakiness SG10201607346XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161521031P 2011-08-08 2011-08-08

Publications (1)

Publication Number Publication Date
SG10201607346XA true SG10201607346XA (en) 2016-10-28

Family

ID=47668720

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201607346XA SG10201607346XA (en) 2011-08-08 2012-08-08 Angiopoietin-like 4 and its use in modulating cell leakiness
SG10202101995WA SG10202101995WA (en) 2011-08-08 2012-08-08 Angiopoietin-like 4 and its use in modulating cell leakiness

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202101995WA SG10202101995WA (en) 2011-08-08 2012-08-08 Angiopoietin-like 4 and its use in modulating cell leakiness

Country Status (5)

Country Link
US (2) US20140242084A1 (en)
EP (2) EP2742361A4 (en)
CN (2) CN103782177B (en)
SG (2) SG10201607346XA (en)
WO (1) WO2013022406A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201406420XA (en) * 2009-10-14 2014-11-27 Univ Nanyang Tech Antiproliferative agent
SG11201408340SA (en) * 2012-08-14 2015-01-29 Univ Nanyang Tech Angiopoietin-like 4 antibody and a method of its use in cancer treatment
GB201301313D0 (en) 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
WO2015157655A2 (en) * 2014-04-10 2015-10-15 University Of Tennessee Research Foundation Method for predicting response to vegf targeted therapeutics
DK3177642T3 (en) * 2014-08-07 2022-02-21 Novartis Ag ANGIOPOIETIN-LIKE 4 ANTIBODIES AND METHODS OF USING IT
AU2014407088B2 (en) 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
CN106955349A (en) * 2016-01-11 2017-07-18 石家庄以岭药业股份有限公司 Application of the PP1158 4 in protection endothelial barrier function
CN106822873B (en) * 2017-02-24 2020-07-03 山东大学 Application of mature form IL-37 in preparing medicine for inhibiting tumor metastasis
EP4072562A4 (en) * 2019-12-09 2023-12-20 Empirico Inc. Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases
CN111549000B (en) * 2020-06-18 2022-07-29 中国医学科学院整形外科医院 Recombinant adipose-derived stem cell for over-expression of Hpgds, preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2339789T3 (en) * 2004-07-20 2010-05-25 Genentech, Inc. PROTEIN 4 INHIBITORS OF ANGIOPOYETINE TYPE, COMBINATIONS AND ITS USE.
LT1781698T (en) * 2004-07-20 2016-09-26 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
US7655762B2 (en) * 2005-01-07 2010-02-02 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against ANGPTL4
SG10201406420XA (en) * 2009-10-14 2014-11-27 Univ Nanyang Tech Antiproliferative agent

Also Published As

Publication number Publication date
EP3399316A1 (en) 2018-11-07
CN107536847A (en) 2018-01-05
EP2742361A1 (en) 2014-06-18
CN103782177A (en) 2014-05-07
US20140242084A1 (en) 2014-08-28
EP2742361A4 (en) 2015-03-04
WO2013022406A1 (en) 2013-02-14
US20180319878A1 (en) 2018-11-08
CN103782177B (en) 2017-10-03
SG10202101995WA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
SG10202101995WA (en) Angiopoietin-like 4 and its use in modulating cell leakiness
IL221511A (en) Bisaryl-linked aryltriazolones and their use
IL227678B (en) Triterpenoids modified in positions 3 and 17
EP2600878A4 (en) Regulatory b cells and their uses
HK1184488A1 (en) Human facilitating cells and uses thereof
ZA201208173B (en) Peptices and their use
IL225713A0 (en) Cytopheretic cartridge and use thereof
IL239588A0 (en) Conserving battery and data usage
PL2916855T3 (en) Collagen hydrolyzate and use thereof
ZA201304235B (en) Oprf/i agents and their use in hospitalized and other patients
EP2762129A4 (en) Cosmetic composition and cosmetic
HK1211419A1 (en) Improvements in water storage devices and apparatuses therefor
PL2648715T3 (en) Carnosine-hyaluronic acid mixtures and their use
EP2619571A4 (en) Human b1 cells and uses thereof
ZA201206667B (en) Improvements in and relating to implements
GB201212724D0 (en) Azaphthalocyanines and their use in ink-jet printing
GB201004417D0 (en) Azaphthalocyanines and their use in ink-jet printing
GB201021105D0 (en) Improvements in and relating to parathas
GB201223300D0 (en) Improvements in or relating to storage and display
GB201223305D0 (en) Improvements in or relating to storage and display
GB201223301D0 (en) Improvements in or relating to storage and display
GB201201848D0 (en) Improvements in or relating to storage and display
GB201201847D0 (en) Improvements in or relating to storage and display
GB201021553D0 (en) Improvements in or relating to storage and display
GB201021548D0 (en) Improvements in or relating to storage and display